Core Viewpoint - Defence Therapeutics Inc. is conducting a non-brokered private placement of debenture units to raise up to $1,200,000, aimed at enhancing its drug delivery technologies [1][2]. Financing Details - The offering consists of debenture units priced at $1,000 each, with a total gross proceeds target of $1,200,000 [1]. - Each unit includes one $1,000 principal amount of an 8.0% convertible debenture and 1,666 common share purchase warrants [1][2]. - The debentures will bear an interest rate of 8.0% per annum and will mature two years from the issue date [2]. - The principal amount of each debenture is convertible into common shares at a conversion price of $0.60 per share [2]. - Accrued interest can be paid annually in shares at the conversion price or in cash at the company's discretion [2]. Warrant Details - Each warrant allows the holder to acquire one common share at an exercise price of $0.75 for a period of two years from the issue date [3]. Regulatory and Compliance Information - All securities issued will be subject to a statutory hold period of four months and one day following the closing date [4]. - The completion of the offering is contingent upon receiving all necessary regulatory approvals [4]. - The company may pay a finder's fee to eligible arm's length finders in accordance with Canadian Securities Exchange policies [4]. Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology, which enhances the precision delivery of ADCs to target cells, thereby increasing efficacy against cancer [6].

Core Insights - Defence Therapeutics Inc. is advancing its ADC and Radiopharma programs, focusing on collaborations and preclinical studies for cancer therapies using its Accum® technology [1][2][3] ADC Program - Defence's Accum®-based ADCs show improved intracellular delivery and cytotoxic activity in various preclinical cancer models compared to traditional ADCs [2] - The company is optimizing additional Accum®-based ADCs to enhance their value and attract potential licensing and co-development opportunities with Pharmaceuticals and Biotech companies [2] Radiopharmaceutical Program - The Radiopharma program is enhancing Accum® radiolabelling through studies conducted by Canadian Nuclear Laboratories, focusing on biodistribution, pharmacokinetics, and therapeutic potency [3] - The application of Accum® technology in the radiopharmaceuticals sector is expected to be transformative [3] Market Outlook - The global ADC market is projected to grow from USD 13.51 billion in 2025 to USD 29.9 billion by 2034, with a CAGR of 9.23% from 2024 to 2034 [4] - The global radiopharmaceutical market is expected to reach USD 16.87 billion by 2033, growing at a CAGR of 9.9% during 2025-2033 [4] Future Developments - The company plans to announce key results and partnership details as they become available, while continuing its studies in Canada and expanding its presence to the US [5] - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology [6]